Bone density, microarchitecture, and tissue quality after 1 year of treatment with tenofovir disoproxil fumarate. (24th April 2018)

• Record Type: Journal Article
• Authors: Güerri-Fernández, Robert; Lerma-Chippirraz, Elisabet; Fernandez Marron, Ana; García-Giralt, Natalia; Villar-García, Judit; Soldado-Folgado, Jade; González-Mena, Alicia; Trenchs-Rodríguez, Marta; Guelar, Ana; Díez-Pérez, Adolfo; Brown, Todd T.; Knobel, Hernando
• Is Part Of: AIDS. Volume 32:Number 7(2018)
• Publication Date: 2018-04-24
• Subjects: bone quality -- bone toxicity -- HIV -- tenofovir; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000001780
• Languages: English
• ISSNs: 0269-9370

Abstract

Abstract : Objecive: Bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) is used to assess bone health in HIV patients. DXA measures the amount of mineral, but not other key aspects of bone strength such as bone microarchitecture or bone quality. Trabecular bone score (TBS) and in-vivo microindentation directly measure trabecular microarchitecture and bone tissue quality, respectively. The aim of this study is to measure bone strength properties using these techniques. Results: Forty naive HIV patients who were going to start antiretroviral therapy (ART), a single pill treatment with elvitegravir/cobicistat, tenofovir disoproxil fumarate (TDF), emtricitavine (FTC) were included. A significant reduction in BMD at spine (−3.25%, P < 0.001) and in femoral neck (−3.82%, P = 0.016) between baseline and 48 weeks of treatment were found. Bone microarchitecture score at the spine, as measured by TBS, also significantly decreased from 1.357 (0.09) to 1.322 (0.09) (−2.5%, P = 0.011) between baseline to 48 weeks of treatment. Microindentation (BMSi) values were significantly higher than at baseline [89.04 (4.2) versus 86.07 (6.1); 3.49%, P < 0.001] after 48 weeks of TDF-based ART treatment, indicating improved bone material properties Conclusion: A significant decrease in BMD and TBS were observed after 1 year of TDF therapy. However, tissue quality significantly improved after 1 year of treatment, suggesting a recovery of bone material properties following the control of the infection despite the significant reduction of BMD. These techniques provide additional and necessary information to DXA about bone health in treated HIV patients, and because of its convenience and feasibility they could be routinely apply to assess bone in clinical practice.